Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs - 2Israel scales back use of top missile interceptors as Iran barrages persist
- 3Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
- 4Members of Kenya-led security mission in Haiti were involved in rapes, U.N. says
- 5Unsold Rams May Be Less expensive Than You Suspect
- Alleged Huione Group Money Laundering Boss Extradited to China
- The Force of Mentorship: Self-improvement through Direction
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
- Malaysian broadcaster rejects altered graphic about electricity rate hike
- What's your biological age? Experts explain the benefits and risks of at-home tests
- EU top diplomat Kallas arrives in Kiev to commemorate Bucha massacre
- Unraveling the Specialty of Picking Your Ideal Travel Objective
- Damaged Shenzhou-20 spacecraft to return to Earth uncrewed for inspection
- Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight
